A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes
Latest Information Update: 25 Oct 2022
At a glance
- Drugs NNC0363-0845 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 20 Oct 2022 Status changed from recruiting to completed.
- 06 Dec 2021 Status changed from not yet recruiting to recruiting.
- 30 Nov 2021 Planned End Date changed from 29 Apr 2022 to 3 Jun 2022.